Clinical trials: Peripheral Vascular Diseases
Thrombophlebitis
Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis
The optimal treatment of superficial venous thrombosis (SVT) is still uncertain. Though low molecular weight heparin (LMWH) is considered the treatment of choice, studies conducted so far do not give clear indications of the…
- Trial name
- NCT00362947
- Testing
- LMWH parnaparin subcutaneously
- Where
- 2 sites in Italy
- Volunteers
- 664 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Peripheral Arterial Disease (PAD)
An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs
This is an observational study in which data already collected from people with peripheral arterial diseases (PAD) who had a surgery to improve blood flow to their legs are studied.
- Trial name
- NCT07142655
- Where
- Japan
- Volunteers
- 1,500 people
- Sponsor
- Bayer
Multiple Myeloma and Plasma Cell Neoplasm
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Giving bortezomib as maintenance therapy after autologous stem cell transplantation may kill more cancer cells and…
- Trial name
- NCT00084747
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Diabetic Retinopathy
Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
This will be a 24 month phase IV, randomised, prospective, multicentre, clinical trial of laser therapy to areas of peripheral retinal ischaemia combined with intravitreal aflibercept versus intravitreal aflibercept monotherapy.
- Trial name
- LADAMO (NCT02432547)
- Testing
- Aflibercept, Targeted laser therapy
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- University of Sydney
Peripheral Arterial Disease, Peripheral Vascular Disease
A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System
The Jetstream System is a commercially available rotating, aspirating, expandable catheter designed to remove atherosclerotic plaque and blood clots in the lower limbs.
- Trial name
- NCT00911417
- Testing
- Pathway Jetstream Atherectomy System
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pathway Medical Technologies Inc.
Raynaud Disease
Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Patients with Raynaud's phenomenon suffer from painful attacks triggered by stress or cold causing acute lowering of blood flow through the digits.
- Trial name
- DIGIT (NCT01926847)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Peripheral Arterial Diseases
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.
- Trial name
- APOLLO (NCT03469349)
- Testing
- Actovegin
- Where
- 20 sites in Georgia, Kazakhstan and 1 more
- Volunteers
- 366 people
- Sponsor
- Takeda
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Peripheral Arterial Disease
TurboHawk™ Japan Trial in Patients With PAD
The objective of this study is to evaluate the safety and effectiveness of the TurboHawk for the treatment of peripheral arterial disease (PAD) in the superficial femoral and/or the popliteal arteries with the Japanese population.
- Trial name
- NCT02169921
- Testing
- Atherectomy Catheter
- Where
- 2 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Medtronic Endovascular
Peripheral Vascular Disease, Claudication
Oral Nutritional Supplement in Reducing Surgical Site Infections
The study aims to evaluate the efficacy of an arginine enriched oral nutritional supplement in the prevention of wound complications in the the wounds of patients post lower limb revascularization.
- Trial name
- NCT02475525
- Testing
- Arginine enriched oral nutritional supplement
- Where
- Ireland
- Volunteers
- 6 people
- Sponsor
- University of Limerick
Peripheral Arterial Occlusive Disease
The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation
The aim of this study was to investigate the effect of a 24- hrs L-arginine infusion on hemodynamic and on parameters of microcirculation in patients with peripheral arterial occlusive disease (PAOD).
- Trial name
- NCT01682889
- Testing
- Arginine
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical Scientific Fund of the Mayor of Vienna
Peripheral Vascular Disease
Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System
The objective of this clinical investigation is to evaluate, in a controlled setting, the long-term (up to 12 months) safety and efficacy of the BeGraft Peripheral Stent Graft System (Bentley InnoMed) in clincial settings post…
- Trial name
- NCT02211716
- Testing
- BeGraft Peripheral Stent Graft System
- Where
- 4 sites in Belgium
- Volunteers
- 70 people
- Sponsor
- Flanders Medical Research Program
Peripheral Artery Disease
Online Support for Outpatient Peripheral Arterial Disease Self-management
This study looks to examine whether an online patient tool to monitor factors affecting patients peripheral artery disease can lead to improvements in patients' disease and slow its progression.
- Trial name
- NCT03464006
- Testing
- Online Support Module, Standard of Care
- Volunteers
- 200 people
- Sponsor
- McMaster University
Peripheral Artery Disease
Comprehensive Magnetic Resonance of Peripheral Arterial Disease
The purpose of this study is to develop new ways of imaging fatty blockages in the leg arteries to improve upon techniques used now and to develop new ways of understanding how new treatments may affect the disease.
- Trial name
- NCT00587678
- Testing
- Simvastatin, Ezetimibe, Simvastatin/Ezetimibe
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Virginia
Peripheral Artery Disease, Femoropopliteal Artery Occlusion
LEVANT 2 Safety Registry
The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in…
- Conditions
- Peripheral Artery Disease, Femoropopliteal Artery Occlusion, Femoropopliteal Stenosis
- Trial name
- NCT01790243
- Testing
- Lutonix Drug Coated Balloon, Standard PTA Balloon
- Where
- 8 sites in United States
- Volunteers
- 1,189 people
- Sponsor
- C. R. Bard
Critical Limb Ischemia (CLI), Diabetes
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients
A prospective, multicenter, open, randomized, parallel-group controlled study for two levels of dose. The study population will consist of 30 non-diabetic patients with critical chronic ischemia in at least one of the lower limbs…
- Trial name
- NCT01257776
- Testing
- Autologous adipose derived mesenchymal stem cells
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Peripheral Arterial Disease
STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of the Stellarex 035 Drug Coated Balloon (formerly known as the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter) in…
- Trial name
- ILLUMENATE (NCT01927068)
- Testing
- Stellarex 0.035" Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 499 people
- Sponsor
- Spectranetics Corporation
Heart Failure, Systolic, Heart Failure, Diastolic
Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status
The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle.
- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic, Peripheral Arterial Disease, Overweight and Obesity
- Trial name
- NCT06009276
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Virginia
Peripheral Arterial Disease
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
Magnesium exerts analgesic effects in several animal pain models and in patients affected by acute postoperative pain and chronic pain of neuropathic origin.
- Trial name
- NCT02455726
- Testing
- Magnesium oxide, Fructose, Oxycodone
- Volunteers
- 150 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Arterial Occlusive Diseases
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
Primary objective: To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100 mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in patients receiving a below knee…
- Trial name
- NCT00174759
- Testing
- Clopidogrel
- Where
- 14 sites in Australia, Austria and 12 more
- Volunteers
- 1,460 people
- Sponsor
- Sanofi